Wave Life Sciences (WVE) Aktienübersicht
Wave Life Sciences Ltd. ist ein Biotechnologieunternehmen in der klinischen Phase, das mit Hilfe von PRISM, einer Plattform für die Entdeckung und Entwicklung von Arzneimitteln, Medikamente auf der Basis von Ribonukleinsäure (RNA) konzipiert, entwickelt und vermarktet. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 0/6 |
| Künftiges Wachstum | 2/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 6/6 |
| Dividenden | 0/6 |
WVE Community Fair Values
Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Wave Life Sciences Ltd. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$5.75 |
| 52-Wochen-Hoch | US$21.73 |
| 52-Wochen-Tief | US$5.02 |
| Beta | -1.33 |
| 1 Monat Veränderung | -9.87% |
| 3 Monate Veränderung | -9.66% |
| 1 Jahr Veränderung | -18.21% |
| 3 Jahre Veränderung | 59.28% |
| 5 Jahre Veränderung | -14.69% |
| Veränderung seit IPO | -64.06% |
Aktuelle Nachrichten und Updates
Narrativ-Update • Jun 22
WVE: RNA Editing Data Readouts Will Drive Future Upside Potential
Analysts have adjusted their price targets for Wave Life Sciences, with one firm lifting its target to $14 from $13 on stronger WVE-007 data. Others reduced targets into the low to mid teens after WVE-006 and competitive readouts led them to temper expectations and reassess probabilities of success.Analyseartikel • Jun 16
Wave Life Sciences (WVE) Stock Could Be 73% Undervalued After WVE 006 Data
Wave Life Sciences (WVE) is back in focus after recent data updates on its RNA editing platform, where lead program WVE-006 for alpha-1 antitrypsin deficiency showed dose-responsive, durable editing and an encouraging safety profile. See our latest analysis for Wave Life Sciences. Despite the encouraging WVE-006 data, Wave Life Sciences’ recent share price return has been weak. The stock is at US$6.00 after a 90-day share price decline of 51.85% and a year to date decline of 62.38%, while the...Narrativ-Update • Jun 06
WVE: RNA Editing Pipeline And Obesity Data Will Shape Future Upside
Analysts have adjusted their price targets on Wave Life Sciences, with one firm lifting its target to $14 from $13 while several others reduced theirs, reflecting mixed views on WVE-006 and WVE-007 data as well as competition from peers such as BEAM-302 and Sanofi. Analyst Commentary Street research on Wave Life Sciences currently reflects a wide range of views, with some firms trimming targets and others increasing them or reaffirming positive stances after recent data updates and management meetings.Recent updates
Narrativ-Update • Jun 22
WVE: RNA Editing Data Readouts Will Drive Future Upside Potential
Analysts have adjusted their price targets for Wave Life Sciences, with one firm lifting its target to $14 from $13 on stronger WVE-007 data. Others reduced targets into the low to mid teens after WVE-006 and competitive readouts led them to temper expectations and reassess probabilities of success.Analyseartikel • Jun 16
Wave Life Sciences (WVE) Stock Could Be 73% Undervalued After WVE 006 Data
Wave Life Sciences (WVE) is back in focus after recent data updates on its RNA editing platform, where lead program WVE-006 for alpha-1 antitrypsin deficiency showed dose-responsive, durable editing and an encouraging safety profile. See our latest analysis for Wave Life Sciences. Despite the encouraging WVE-006 data, Wave Life Sciences’ recent share price return has been weak. The stock is at US$6.00 after a 90-day share price decline of 51.85% and a year to date decline of 62.38%, while the...Narrativ-Update • Jun 06
WVE: RNA Editing Pipeline And Obesity Data Will Shape Future Upside
Analysts have adjusted their price targets on Wave Life Sciences, with one firm lifting its target to $14 from $13 while several others reduced theirs, reflecting mixed views on WVE-006 and WVE-007 data as well as competition from peers such as BEAM-302 and Sanofi. Analyst Commentary Street research on Wave Life Sciences currently reflects a wide range of views, with some firms trimming targets and others increasing them or reaffirming positive stances after recent data updates and management meetings.Narrativ-Update • May 23
WVE: Obesity Program Data And RNA Editing Validation Will Drive Future Upside
Wave Life Sciences' analyst price target has been revised lower from $49.99 to $40.15 as analysts factor in mixed readouts for WVE-006 and WVE-007, tougher competition from peers, and updated probabilities of success, although some firms still see room for upside based on recent pipeline data. Analyst Commentary Recent Street research on Wave Life Sciences reflects a split view, with some firms cutting targets after recent data updates and others highlighting what they see as attractive upside if the company executes on its current programs.Seeking Alpha • May 20
Wave Life Sciences: 'Strong Buy' On DMD NDA Filing WVE-N531 And Released AATD Data
Summary Wave Life Sciences Ltd. retains a Strong Buy rating, driven by near-term Accelerated Approval catalysts for WVE-N531 and WVE-006. The company is on track to file an NDA for WVE-N531 in DMD exon 53 skipping in 2026, targeting approval based on dystrophin production and functional testing. Recent phase 1b/2a data for WVE-006 in AATD showed up to 70.5% Z-AAT reduction with multi-dosing, with key FDA feedback and 600 mg multi-dose data expected in mid/late 2026. WVE's robust $544.6M cash balance funds operations into Q3 2028, supporting continued pipeline advancement and multiple potential inflection points. Read the full article on Seeking Alpha
Narrativ-Update • May 04
WVE: Obesity Data And 2026 Catalysts Will Shape Future Upside
Analysts have reduced their price targets on Wave Life Sciences, driving an internal fair value estimate from about $34.06 to $22.19 as they factor in updated revenue growth, margin expectations, and pipeline competitiveness against GLP-1 treatments. Analyst Commentary Recent research coverage on Wave Life Sciences has become more mixed, with a cluster of price target cuts around updated obesity data and GLP-1 competition, alongside a smaller group of firms that remain constructive on the pipeline and long term opportunity.Narrativ-Update • Apr 19
WVE: Obesity And AATD Pipeline Progress Will Drive Future Upside
Analysts have reduced the average price target for Wave Life Sciences by about $1, reflecting a mix of lower Street targets after recent obesity and GLP-1 competitiveness concerns, partly offset by a few upward revisions following pipeline updates. Analyst Commentary Recent Street commentary around Wave Life Sciences has been mixed, with several firms cutting price targets and questioning the competitiveness of the obesity and GLP 1 pipeline, while a smaller group of bullish analysts has highlighted potential upside tied to clinical catalysts and management execution.Narrativ-Update • Apr 05
WVE: Obesity Pipeline Data And Regulatory Pathways Will Drive Future Upside
Analysts have adjusted the fair value estimate for Wave Life Sciences to $50.75 from $45.17, reflecting updated views on its obesity and AATD pipeline opportunities, as well as a mix of recent price target revisions across the Street. Analyst Commentary Recent research on Wave Life Sciences shows a split tape, with some firms turning more cautious while others highlight potential value in the obesity and AATD programs.Narrativ-Update • Mar 22
WVE: Obesity Data And 2026 AATD Milestones Will Drive Future Upside
Analysts have nudged the fair value estimate for Wave Life Sciences to $34.06 from $33.50, reflecting updated views on its obesity and AATD pipeline progress and higher future P/E assumptions informed by recent price target revisions across the Street. Analyst Commentary Street research on Wave Life Sciences is centering on the obesity and AATD programs, with several firms updating their targets and models after recent management meetings and clinical readouts.Narrativ-Update • Mar 07
WVE: Obesity Fat Reduction Data Will Drive Future Upside Potential
Analysts have inched their fair value estimate for Wave Life Sciences higher from $33.38 to $33.50. This reflects updated views on WVE-007's obesity program and potential regulatory pathways, as well as the recent cluster of higher Street price targets that highlight upcoming data as a key near term catalyst.Narrativ-Update • Feb 20
WVE: INHBE Cardiometabolic Data And AATD Rights Will Drive Future Upside
Analysts have nudged their fair value estimate for Wave Life Sciences higher, with the updated target moving from about $33.06 to $33.38 as they factor in recent bullish coverage, higher Street price targets, and evolving views on revenue growth, margins, and future P/E assumptions. Analyst Commentary Bullish analysts have recently highlighted Wave Life Sciences as a name to watch, with several research shops updating their views and price targets in quick succession.Narrativ-Update • Feb 06
WVE: INHBE Fat Reduction And AATD Progress Will Drive Future Upside
Analysts increased their price target on Wave Life Sciences by about $1 to roughly $33 per share, as recent bullish coverage and supportive data for its INHBE-targeting approach and AATD program reinforced confidence in the company's long term potential. This was viewed as justification for a higher fair value estimate despite a slightly higher discount rate and modestly adjusted growth and margin assumptions.Narrativ-Update • Jan 22
WVE: Obesity And RNA Editing Progress Will Drive Future Upside Potential
Analysts have lifted their price targets on Wave Life Sciences, with our fair value estimate moving from US$32.60 to about US$45.17. This reflects growing confidence in its INHBE-targeting obesity program, validation of its RNA editing approach versus competitors, and supportive commentary around its Huntington’s disease and weight loss pipelines.Narrativ-Update • Jan 08
WVE: INHBE Obesity Program Will Drive Future Upside Potential
Analysts have inched up their fair value estimate for Wave Life Sciences to about $31.93 per share from $31.60. This reflects updated views on the company’s INHBE-targeting obesity program, strengthened competitive position in AATD, and continued interest in its broader genetic medicines pipeline.Narrativ-Update • Dec 24
WVE: Obesity RNA Editing Advances Are Expected To Drive Future Upside
Analysts have lifted their fair value estimate for Wave Life Sciences to approximately $31.60 per share from about $27.21, citing strengthened competitive positioning in genetic medicines, positive obesity pipeline data, and limited negative read-throughs from peer setbacks as key drivers. Analyst Commentary Bullish analysts highlight that recent competitive developments in alpha-1 antitrypsin deficiency have effectively de-risked Wave Life Sciences' editing approach, supporting higher confidence in long term market share and cash flow potential.Analyseartikel • Dec 16
Subdued Growth No Barrier To Wave Life Sciences Ltd. (NASDAQ:WVE) With Shares Advancing 128%
The Wave Life Sciences Ltd. ( NASDAQ:WVE ) share price has done very well over the last month, posting an excellent...Narrativ-Update • Dec 10
WVE: Obesity RNA Editing Breakthrough Is Expected To Drive Future Upside
Analysts have raised their price target on Wave Life Sciences by about $7 per share, reflecting increased confidence in the companys validated RNA editing approach, its expanding obesity pipeline, and its insulated Huntington's disease program despite sector specific setbacks. Analyst Commentary Bullish analysts view recent sector developments as reinforcing Wave Life Sciences competitive positioning, particularly in RNA editing and obesity, and see room for further upside as the company executes on its clinical milestones.Analyseartikel • Nov 01
Wave Life Sciences Ltd. (NASDAQ:WVE) Stock Rockets 29% As Investors Are Less Pessimistic Than Expected
Wave Life Sciences Ltd. ( NASDAQ:WVE ) shares have had a really impressive month, gaining 29% after a shaky period...Analyseartikel • Sep 14
Wave Life Sciences Ltd. (NASDAQ:WVE) Shares May Have Slumped 29% But Getting In Cheap Is Still Unlikely
Wave Life Sciences Ltd. ( NASDAQ:WVE ) shares have retraced a considerable 29% in the last month, reversing a fair...Analyseartikel • Aug 04
Wave Life Sciences Ltd. (NASDAQ:WVE) Analysts Just Trimmed Their Revenue Forecasts By 13%
One thing we could say about the analysts on Wave Life Sciences Ltd. ( NASDAQ:WVE ) - they aren't optimistic, having...Analyseartikel • Jul 31
Wave Life Sciences Ltd.'s (NASDAQ:WVE) 26% Share Price Surge Not Quite Adding Up
Wave Life Sciences Ltd. ( NASDAQ:WVE ) shareholders would be excited to see that the share price has had a great month...Analyseartikel • Jul 07
We Think Wave Life Sciences (NASDAQ:WVE) Needs To Drive Business Growth Carefully
We can readily understand why investors are attracted to unprofitable companies. For example, although...Analyseartikel • Jun 01
Risks Still Elevated At These Prices As Wave Life Sciences Ltd. (NASDAQ:WVE) Shares Dive 26%
Unfortunately for some shareholders, the Wave Life Sciences Ltd. ( NASDAQ:WVE ) share price has dived 26% in the last...Analyseartikel • Apr 04
Wave Life Sciences Ltd.'s (NASDAQ:WVE) 41% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Unfortunately for some shareholders, the Wave Life Sciences Ltd. ( NASDAQ:WVE ) share price has dived 41% in the last...Seeking Alpha • Mar 27
Wave Life Sciences: Potential For Accelerated Approval Pathway With WVE-N531
Summary Wave Life Sciences Ltd. release of multi-dose data from the phase 1b/2a open-label RestorAAtion-2 study, using WVE-006 for AATD-related lung disease, expected in 2025. Positive results were achieved in the phase 2 FORWARD-53 study, using WVE-N531 for the treatment of patients with DMD amenable to exon 53 skipping; an average dystrophin expression of 7.8% was achieved. The Duchenne Muscular Dystrophy market, in the 7 major markets, will reach $5.2 billion by 2033. Positive FDA meeting held; potential for WVE to file for Accelerated Approval of WVE-N531 for DMD patients amenable to Exon 53 skipping in 2026. Read the full article on Seeking Alpha
Neues Narrativ • Mar 23
WVE-007 And WVE-006 Will Offer New Treatment Options For Obesity And AATD
Advancing innovative treatments like WVE-007 and WVE-006 could drive revenue growth by addressing current therapy limitations and capturing market share in obesity and AATD.Seeking Alpha • Jan 08
Wave Life Sciences Is A Buy On Pipeline Prospects
Summary Wave Life Sciences develops stereopure oligonucleotides targeting genetic mutations, with lead assets in DMD, AATD, and Huntington's Disease showing promising data. Major collaborations with GSK and positive trial results have significantly boosted WVE's stock, despite previous flat performance and management missteps. Financially strong with $525M in cash, the Company has a solid runway for 8–10 quarters, though approval for its programs is still years away. Despite valuation risks, WVE's successful data, collaborations, and large target markets make it a buy; start small, accumulate at dips, and hold long term. Read the full article on Seeking AlphaAnalyseartikel • Nov 15
US$22.20 - That's What Analysts Think Wave Life Sciences Ltd. (NASDAQ:WVE) Is Worth After These Results
Wave Life Sciences Ltd. ( NASDAQ:WVE ) missed earnings with its latest quarterly results, disappointing...Analyseartikel • Nov 09
Optimistic Investors Push Wave Life Sciences Ltd. (NASDAQ:WVE) Shares Up 95% But Growth Is Lacking
Despite an already strong run, Wave Life Sciences Ltd. ( NASDAQ:WVE ) shares have been powering on, with a gain of 95...Seeking Alpha • Oct 16
Wave Life Sciences: Positive WVE-006 Data For AATD Leads To 2025 Catalyst
Summary Wave Life Sciences announced positive results from its phase 1b/2a RestorAAtion-2 study using WVE-006 for the treatment of alpha-1 antitrypsin deficiency patients. A single subcutaneous administration of 200 mg of WVE-006 resulted in the presence of wild-type alpha-1 antitrypsin protein; This led to a more than 60% increase of AAT. The global Alpha-1 Antitrypsin Deficiency market is expected to reach a $10 billion market value by 2033. Additional results from the phase 1b/2a RestorAAtion-2 study using WVE-006 for the treatment of patients with alpha-1 Antitrypsin Deficiency, expected in 2025. Read the full article on Seeking AlphaAnalyseartikel • Sep 25
There's Reason For Concern Over Wave Life Sciences Ltd.'s (NASDAQ:WVE) Massive 43% Price Jump
Despite an already strong run, Wave Life Sciences Ltd. ( NASDAQ:WVE ) shares have been powering on, with a gain of 43...Seeking Alpha • Sep 24
Wave Life Sciences: Spiking On Strong DMD Data, But Not Fully De-Risked Yet
Summary Wave Life Sciences stock surged over 50% today due to promising data from its Duchenne Muscular Dystrophy candidate WVE-N531, showing >5% dystrophin production. The safety profile of WVE-N531 is strong, but competition from gene therapies and the need for further efficacy data present significant challenges. Investors should consider waiting for 48-week data and clearer regulatory paths before committing, despite WVE stock's current upside potential. Despite past setbacks, Wave's innovative RNA-targeting technology and strategic partnerships, like with GSK, position it for potential breakthroughs in multiple disease areas. A successfully approved DMD candidate could ultimately turn Wave into a double-digit billion company, like rival Sarepta Therapeutics, but that eventuality remains a long way off. Read the full article on Seeking AlphaAnalyseartikel • Sep 08
Broker Revenue Forecasts For Wave Life Sciences Ltd. (NASDAQ:WVE) Are Surging Higher
Shareholders in Wave Life Sciences Ltd. ( NASDAQ:WVE ) may be thrilled to learn that the analysts have just delivered a...Analyseartikel • Aug 05
We're Keeping An Eye On Wave Life Sciences' (NASDAQ:WVE) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Analyseartikel • Jun 25
Pinning Down Wave Life Sciences Ltd.'s (NASDAQ:WVE) P/S Is Difficult Right Now
You may think that with a price-to-sales (or "P/S") ratio of 5.7x Wave Life Sciences Ltd. ( NASDAQ:WVE ) is a stock to...Analyseartikel • Apr 09
We Think Wave Life Sciences (NASDAQ:WVE) Can Easily Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Mar 09
Wave Life Sciences' Weighty Ambition: Carving Out Obesity Niche
Summary Wave Life Sciences is entering the obesity market, selecting INHBE as a clinical candidate. The company faces intense competition from other RNA-based therapeutics companies, such as Alnylam, that have successfully brought treatments to market. Investment recommendation: Hold, due to intense competition, financial sustainability concerns, and current market sentiment. Read the full article on Seeking AlphaAnalyseartikel • Mar 03
Wave Life Sciences Ltd.'s (NASDAQ:WVE) 30% Price Boost Is Out Of Tune With Revenues
Wave Life Sciences Ltd. ( NASDAQ:WVE ) shareholders are no doubt pleased to see that the share price has bounced 30% in...Analyseartikel • Sep 13
We're Interested To See How Wave Life Sciences (NASDAQ:WVE) Uses Its Cash Hoard To Grow
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Aktionärsrenditen
| WVE | US Pharmaceuticals | US Markt | |
|---|---|---|---|
| 7D | -6.7% | 4.1% | -2.7% |
| 1Y | -18.2% | 40.6% | 18.6% |
Rendite im Vergleich zur Industrie: WVE unter dem Niveau der Branche US Pharmaceuticals , die im vergangenen Jahr eine Rendite von 40.6% erzielte.
Rendite vs. Markt: WVE hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 18.6 erzielte.
Preisvolatilität
| WVE volatility | |
|---|---|
| WVE Average Weekly Movement | 16.0% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiler Aktienkurs: Der Aktienkurs von WVE war in den letzten 3 Monaten im Vergleich zum US -Markt volatil.
Volatilität im Zeitverlauf: WVEDie wöchentliche Volatilität der Aktie ist im letzten Jahr von 24% auf 16% gesunken, liegt aber immer noch höher als bei 75% der Aktien von US.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 2012 | 317 | Paul B. Bolno | wavelifesciences.com |
Wave Life Sciences Ltd. ist ein Biotechnologieunternehmen in der klinischen Phase und konzipiert, entwickelt und vermarktet Ribonukleinsäure (RNA)-Medikamente über PRISM, eine Entdeckungs- und Arzneimittelentwicklungsplattform. PRISM, die Arzneimittelplattform des Unternehmens, kombiniert mehrere Modalitäten, chemische Innovationen und tiefe Einblicke in die Humangenetik, um wissenschaftliche Durchbrüche bei der Behandlung seltener und weit verbreiteter Krankheiten zu erzielen. Das Unternehmen entwickelt WVE-006, ein GalNAc-konjugiertes RNA-Editing-Oligonukleotid zur Behandlung des Alpha-1-Antitrypsin-Mangels; WVE-007, eine GalNAc-konjugierte kleine interferierende RNA, die die INHBE-mRNA zum Schweigen bringen soll und auf Fettleibigkeit abzielt; WVE-008, ein GalNAc-konjugiertes RNA-Editier-Oligonukleotid zur Behandlung von Lebererkrankungen; WVE-N531, ein Exon-Splicing-Oligonukleotid zur Behandlung von Duchenne-Muskeldystrophie; und WVE-003, ein allelselektives Oligonukleotid zur Behandlung der Huntington-Krankheit (HD).
Wave Life Sciences Ltd.'s Grundlagenzusammenfassung
| WVE grundlegende Statistiken | |
|---|---|
| Marktanteil | US$1.14b |
| Gewinn(TTM) | -US$183.59m |
| Umsatz(TTM) | US$71.80m |
15.4x
Kurs-Umsatz-Verhältnis-6.0x
Kurs-Gewinn-Verhältnis Ist WVE zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| WVE Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$71.80m |
| Kosten der Einnahmen | US$189.60m |
| Bruttogewinn | -US$117.80m |
| Sonstige Ausgaben | US$65.79m |
| Gewinn | -US$183.59m |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -0.95 |
| Bruttomarge | -164.07% |
| Nettogewinnspanne | -255.70% |
| Schulden/Eigenkapital-Verhältnis | 0% |
Wie hat sich WVE auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/06/25 06:08 |
| Aktienkurs zum Tagesende | 2026/06/25 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Wave Life Sciences Ltd. wird von 28 Analysten beobachtet. 16 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Alec Stranahan | BofA Global Research |
| Madison Wynne El-Saadi | B. Riley Securities, Inc. |
| Whitney Ijem | Canaccord Genuity |